Granules India Limited (GRANULES)
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation - Q2 FY27
- Revenue ₹15,600 Mn +20% YoY; EBITDA ₹3,376 Mn +21% YoY; PAT ₹1,818 Mn +39% YoY
- Gross margin at 64.4%, down 134 bps YoY due to higher input and logistics costs
- Complex generics share at 49% of portfolio, growing 45% YoY; 3 potential sole first-to-file ANDAs filed
- Net cash position ₹828 Cr after warrant proceeds; ROCE improved to 17.6%
- US FDA audit at Gagillapur site constructive; corrective actions underway
- Capex ₹2,194 Mn in H1 FY27; organic capex planned ~₹20,000 Mn over 3-4 years
- North America revenue +14% YoY; Europe +65% YoY; Peptide CDMO segment expanding
- R&D spend 5.7% of sales; 159 dossiers filed globally with 106 approvals
- Sustainability goals progressing with 42% reduction in Scope 1,2,3 emissions by 2030
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GRANULES — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GRANULES to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Granules India Limited
Important.
The summary above is generated automatically from Granules India Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.